Back to Search
Start Over
Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib.
- Source :
- Oncology Research & Treatment; Dec2019, Vol. 42 Issue 12, p660-664, 5p
- Publication Year :
- 2019
-
Abstract
- Background: In elderly patients with chronic myeloid leukemia (CML) responsive to imatinib, the incidence of clinically significant (CS) late chronic anemia is still unknown. Materials and Methods: To highlight this issue, we revised retrospectively 81 CML patients aged >60 years treated at our Institution with front-line imatinib for at least 24 months in durable complete cytogenetic response (CCyR). CS late chronic anemia was defined as the presence of persistent (>6 months) and otherwise unexplained Hb levels ≤10 g/dL, which occurred >6 months from imatinib start. Results: A condition of CS late chronic anemia occurred in 22 out of 81 patients (27.2%) at different intervals from imatinib start. Seven out of 22 patients (31.8%) needed packed red cell transfusions during the follow-up. At diagnosis, patients who developed CS late chronic anemia were significantly older and had a lower Hb median level. Six out of 22 patients with CS late chronic anemia received subcutaneous recombinant alpha-erythropoietin (EPO) at the standard dosage of 40,000 IU weekly: all 6 patients achieved an erythroid response. A significantly worse event-free survival (EFS) in patients with untreated CS late chronic anemia was observed (p = 0.012). Conclusions: CS late chronic anemia during long-term treatment with imatinib is a common complication in responsive elderly patients, with worse EFS if untreated. Results with EPO are encouraging, but larger studies are warranted to define its role. [ABSTRACT FROM AUTHOR]
- Subjects :
- CHRONIC myeloid leukemia
OLDER patients
IMATINIB
ANEMIA
ERYTHROCYTES
CHRONIC leukemia
Subjects
Details
- Language :
- English
- ISSN :
- 22965270
- Volume :
- 42
- Issue :
- 12
- Database :
- Complementary Index
- Journal :
- Oncology Research & Treatment
- Publication Type :
- Academic Journal
- Accession number :
- 140084353
- Full Text :
- https://doi.org/10.1159/000502801